Phase II trial of anti PD-1 monoclonal antibody and FOLFOXIRI combined with long-course radiotherapy
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Low-lying locally advanced rectal cancer (LARC) remains at substantial risk of incomplete tumor response and suboptimal organ preservation despite multimodal therapy. Here we conducted a prospective, single-arm, phase II trial (NCT 06099951) evaluating FOLFOXIRI chemotherapy combined with long-course chemoradiotherapy and PD-1 blockade (serplulimab) in low-lying LARC patients.
Source: China National GeneBank DataBase
DOI: 10.26036/cnp0009362
Author: 康达(Kangda)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7225150954